- Stoke Therapeutics recently shared new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy at the AAO 2026 meeting, alongside progress in the Phase 1 OSPREY dose-escalation trial.
- The presentations connected FALCON natural history findings, OPA1 biology and OSPREY readouts, giving investors a clearer view of how STK-002 could fit into Stoke Therapeutics' rare ophthalmology pipeline, where no approved ADOA treatments currently exist.
- We will now look at how Stoke Therapeutics' investment narrative could be shaped by STK-002's early ADOA data and trial progress.
Scan beyond Stoke Therapeutics and line up other rare disease opportunities with the hand picked 20 high quality undiscovered gems that could sit beside a high-risk pipeline bet such as STOK.
Stoke Therapeutics Investment Narrative Recap
To own Stoke Therapeutics, you need to believe its antisense platform can translate into approved drugs in rare CNS and eye disorders. Zorevunersen in Dravet syndrome still looks like the key value driver, with the long Phase 3 EMPEROR readout and NDA path shaping the near term outlook. The recent STK-002 AAO data expand the story but do not change the central role of EMPEROR and regulatory decisions in Dravet.
The biggest operational risk remains clinical or regulatory setbacks that delay or limit zorevunersen or reveal safety constraints as exposure builds. STK-002 progress increases platform breadth but also extends the period of heavy R&D spend while the business is still loss making, so any requirement for extra data or slower enrollment across programs could keep cash burn elevated for longer.
The most relevant linked update is Stoke’s October 5 meeting with the FDA on the planned New Drug Application for zorevunersen in Dravet syndrome. That interaction framed how five years of safety and efficacy data, along with EMPEROR’s seizure and Vineland 3 subdomain results, are expected to be packaged and analyzed for U.S. review.
For you as an investor, that zorevunersen plan sets the main commercial catalyst and timing reference point, while the AAO 2026 STK-002 data speak to optionality beyond Dravet. Together they highlight an execution challenge for Stoke Therapeutics, which is running an expensive late stage epilepsy program and an early ophthalmology effort at the same time, both with clinical, payer and partner risk attached.
Stoke Therapeutics’ current analyst narrative points to US$177.8 million in revenue and US$33.6 million in earnings by 2029. This outlook is built on a forecast 77.0% yearly revenue growth rate and a swing in earnings of roughly US$203 million, from a loss of US$169.8 million today to the projected 2029 profit.
Uncover how Stoke Therapeutics' fair value indicates a potential 87% upside to its current price before the market closes that discount.
Exploring Other Perspectives
One alternate view focuses on payer risk rather than trial outcomes. The most cautious analysts worry that tight reimbursement for zorevunersen could slow Stoke Therapeutics’ earnings ramp. Before the AAO news, this group was using revenue of about US$23.1 million and earnings of roughly US$4.4 million by 2029, which leaves room for sentiment to shift as new data arrive.
Explore 3 other Stoke Therapeutics fair value estimates, including one that suggests it could be worth just $35.00!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Stoke Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Stoke Therapeutics?
Once you have a handle on Stoke Therapeutics and its risk reward profile, it often helps to line it up against very different types of opportunities so you can balance high conviction views with diversification.
- For investors who prefer financially resilient businesses that can help anchor a portfolio, review our list of solid balance sheet and fundamentals (25 results) and see which assets might provide that foundation.
- If your priority is cushioning volatility with income, scan through the 8 dividend fortresses and see which payers could complement a higher risk biotech position.
- For those looking for mispriced opportunities with stronger fundamentals, compare Stoke Therapeutics against the 33 high quality undervalued stocks and see where the market may be leaving room for potential benefits.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com